Furthermore, the examined association between RNF122 mRNA levels and clinicopathological characteristics in 112 glioma patients (Table S1) revealed that the RNF122 mRNA expression level had a significant correlation to the tumor size (p < 0.001), KPS (p < 0.001), and WHO stage (p < 0.001). This evidence concerns the gene RNF122 and central nervous system cancer.